Navigation Links
Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
Date:2/17/2009

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
6. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
7. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
8. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
9. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
10. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
11. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... CGM System as a non-invasive, wireless continuous glucose ... Doman , Executive Chairman and Interim CEO of ... Capital Markets, Tenth Annual Equity Conference. ... to prospective corporate partners and investors at 9:00 ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Dermatitis - India Drug Forecast and Market ... PharmaPoint: Atopic Dermatitis - ... 2022 Summary,Although the past decade ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ... in body fat content and preserved lean body ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... CUPERTINO, Calif. , July 1 DURECT Corporation (Nasdaq: DRRX ... which it may sell up to $50 million of its registered ... is not obligated to utilize any of the $50 million facility. ... this facility. , , , ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd.,(Nasdaq: DHRM ), an emerging ... medical products in China , said today,that Rita Zheng Liu ... will present at the Global Hunter,Securities 2010 China Conference to be held ... , , ...
Cached Medicine Technology:DURECT Corporation Secures $50 Million Committed Equity Financing Facility 2DURECT Corporation Secures $50 Million Committed Equity Financing Facility 3Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco 2Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... similar medicines pose big stomach risks, study notes ... of patients don,t tell their doctors that they take ... potentially dangerous omission, a new study has found. , ... medicine intake, it is no wonder that adverse events ...
... four out of ten HIV positive African-American men could be putting ... in the latest UK-based Journal of Advanced Nursing. , A ... that many of the 40 to 65 year-olds were engaging in ... oral sex, with 25 per cent having unprotected vaginal sex and ...
... contribute to heart attack, stroke and dementia, likely also ... researchers say. , Homocysteine levels rise when folic acid ... are often poor in folate-rich fruits, tomatoes, vegetables and ... the Medical College of Georgia. , Scientists want to ...
... Donates Hotel Points to Benefit More Transplant Patients and Family ... ... The National Foundation for,Transplants (NFT) announced today that it will extend free ... to,pre- and post-transplant care through an expansion of its Home Away From,Home ...
... Winners Announced at Annual ASRM Meeting, ... won Ferring,Pharmaceuticals, national 2007 My Little Miracle ... the births of their ,little miracles,children born ... fertility treatments.,The fourth annual contest celebrated the ...
... Oct. 15 Edwards Lifesciences,Corporation (NYSE: EW ), ... cardiovascular disease, plans to announce its operating,results for the ... on,Monday, October 22, 2007 and will host a conference ... results. To participate in the conference call, dial ...
Cached Medicine News:Health News:Many Patients Don't Report Use of OTC Pain Drugs 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 3Health News:Older African-American men with HIV often have sex without condoms 2Health News:Impact of elevated homocysteine levels on vision under study 2Health News:Impact of elevated homocysteine levels on vision under study 3Health News:National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families 2Health News:National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families 3Health News:Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest 2Health News:Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest 3Health News:Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest 4Health News:Edwards Lifesciences to Host Earnings Conference Call on October 22, 2007 2
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: